Abstracts tagged "Natural Killer Cells"

Abstract Number: 2443 • ACR Convergence 2025
Mitochondrial dysfunction drives natural killer cell dysfunction in systemic lupus erythematosus
Natalia Fluder¹, Morgane Humbel², Camillo Ribi¹ and Denis Comte¹, ¹Lausanne University Hospital / University of Lausanne, Lausanne, Switzerland, ²Beth Israel Deaconess Medical Center, Harvard Medical School, Boston
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by immune dysregulation and widespread inflammation. Natural killer (NK) cells, essential for immune surveillance,…
Abstract Number: 1876 • ACR Convergence 2025
Targeting the NK cell checkpoint NKG2A promotes lung fibrosis resolution by enhancing immune clearance of senescent myofibroblasts
Wolfgang Merkt¹, Lea Rodon², Franca Sophie Deicher³, Maren Claus⁴, Rachel Lister⁵, Hongwei Han⁵, Yan Zhou⁵, Zhengwang Sun⁵, Arik Horne⁶, Ayla Nadja Stuetz⁷, Michael Kreuter⁸, nicolas kahn⁹, Marc Schneider⁹, Simon Haas¹⁰, Norbert Blank¹¹, Hanns-Martin Lorenz¹², Carsten Watzl⁴, Daniel Hübschmann¹³ and David Lagares⁵, ¹University Hospital Düsseldorf, Düsseldorf, Germany, ²University Hospital Heidelberg, Heidelberg, Hungary, ³Uniklinik Düsseldorf, Düsseldorf, Germany, ⁴IfADo, Leibniz Institute Dortmund, Dortmund, Germany, ⁵Massachusetts General Hospital and Harvard Medical School, Boston, ⁶Charite, Berlin, Berlin, ⁷Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, ⁸Universitätsmedizin Mainz, Mainz, ⁹Thoraxklinik, Heidelberg University, Heidelberg, Germany, ¹⁰Charite, Berlin, Berlin, Germany, ¹¹University Hospital Heidelberg, Heidelberg, Germany, ¹²Universitétsklinikum Heidelberg, Heidelberg, Germany, ¹³Heidelberg University, Berlin, Germany
Background/Purpose: A key event driving pulmonary fibrosis in interstitial lung disease (ILD) is the accumulation of pathologic senescent myofibroblasts, thought to be promoted by insufficient…
Abstract Number: 1824 • ACR Convergence 2025
Tissue-Resident Natural Killer Cells May Drive Monocyte Differentiation And Macrophage Accumulation In The Inflamed Joints Of Pediatric Juvenile Idiopathic Arthritis Patients
Roselyn Fierkens¹, Jun Inamo², Clara Lin³, Nathan Rogers⁴, Kari Hayes¹, Heather Leach³ and Kentaro Yomogida¹, ¹University of Colorado, Aurora, CO, ²University of Colorado School of Medicine, Aurora, CO, ³Children's Hospital Colorado, Aurora, ⁴Children’s Hospital Colorado, Aurora, CO
Background/Purpose: Natural Killer (NK) cells are the most abundant innate lymphoid cells, accounting for 10–40% of total lymphocytes in peripheral blood. They adapt to diverse…
Abstract Number: 1145 • ACR Convergence 2025
Numerically Reduced but MSU Crystal-Activated NK Cells Promote Osteoclastogenesis in Gout
Ki-Jeong Park¹, Young-Nan Cho², Hye-Mi Jin², Hye-Min Jeong², Sung-Eun Choi³, Ji-Hyoun Kang¹, Dong-Jin Park¹, Tae-jong Kim⁴, Shin-Seok Lee⁵ and Yong-Wook Park⁶, ¹Chonnam National University Hospital, Gwangju, Republic of Korea, ²Chonnam National University Medical School, Gwangju, Republic of Korea, ³Chonnam National University Medical School & Hospital, Gwangju, Republic of Korea, ⁴Department of Rheumatology, Chonnam National University Medical School and Hospital, Gwang-Ju, South Korea, ⁵Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea, ⁶Department of Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea
Background/Purpose: Gout is an inflammatory arthritis characterized by acute attacks, tophi formation, and bone destruction triggered by inflammatory responses to monosodium urate (MSU) crystals. Natural…
Abstract Number: 1094 • ACR Convergence 2025
Changes in NK cells and TH cell phenotype in Rheumatoid Arthritis patients treated with janus kinase inhibitors: implications for adverse effects
Carmen Lasa Teja¹, Juan José Fernández-Cabero², Alejandra Comins-Boo³, David San Segundo³, Virginia Portilla González⁴, Montserrat Santos-Gomez⁵, José Luis Martín-Varillas⁶, Marcos López-Hoyos³ and Ricardo Blanco⁷, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Riotuerto, Cantabria, Spain, ²Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Cantabria, Spain, ³Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ⁴Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, ⁵Division of Immunology, Hospital Sierrallana. Santander , Spain, Santander, Spain, ⁶Rheumatology Division, Hospital de Laredo. IDIVAL, Immunopathology Group. Santander, Spain., Laredo, Spain, ⁷Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Janus kinase inhibitors (JAKi) are effective in rheumatoid arthritis (RA); however, concerns regarding safety, particularly the risk of infections and malignancies, have been raised.…
Abstract Number: 0933 • ACR Convergence 2025
Spatial Transcriptomics Reveal Altered Immune Dynamics Regulating Placental Development In a Humanized-TLR8 Mouse Model of Spontaneous Anti-Phospholipid Antibody Induced Pregnancy Loss
Yunwei Xia¹, Paul Hoover², Arnon Arazi³ and Anne Davidson¹, ¹Feinstein Institutes for Medical Research, Manhasset, NY, ²Brigham and Women's Hospital, Boston, MA, ³Feinstein Institutes for Medical Research, Acton, MA
Background/Purpose: TLR8 has been implicated in adverse outcomes of human pregnancy. We previously reported a mouse model of spontaneous aPL-induced pregnancy loss in Sle1 mice…
Abstract Number: 0932 • ACR Convergence 2025
Compartment-specific NK-cell phenotypes reveal distinct maturation and activation states in inflammatory arthritis
Franca Sophie Deicher¹, Tarik Exner², Maren Claus³, Schayan Yousefian⁴, Lea Rodon⁵, sophie leonhardt⁶, Jörg Distler⁷, Carsten Watzl³, Hanns-Martin Lorenz⁸, Simon Haas⁴, Daniel Hübschmann⁹ and Wolfgang Merkt¹⁰, ¹Uniklinik Düsseldorf, Düsseldorf, Germany, ²University Hospital Heidelberg, Heidelberg, Germany, ³IfADo, Leibniz Institute Dortmund, Dortmund, Germany, ⁴Charite, Berlin, Berlin, Germany, ⁵University Hospital Heidelberg, Heidelberg, Hungary, ⁶Heidelberg University, Heidelberg, Germany, ⁷University Hospital Duesseldorf and HHU, Duesseldorf, Germany, ⁸Universitétsklinikum Heidelberg, Heidelberg, Germany, ⁹Heidelberg University, Berlin, Germany, ¹⁰University Hospital Düsseldorf, Düsseldorf, Germany
Background/Purpose: Synovial natural killer (NK) cells contribute to inflammation in arthritis by secreting cytokines and modulating synovial fibroblast activation. The aim of this study is…
Abstract Number: 0039 • ACR Convergence 2025
Hemophagocytic Lymphohistiocytosis Gene Variants in Severe COVID-19 Cytokine Storm Syndrome
randy Cron¹, Abhishek Kamath¹, Mingce Zhang¹, Devin Abhser², Lesley Jackson¹ and Walter Winn Chatham³, ¹University of Alabama at Birmingham, Birmingham, AL, ²Kaiser Permanente Research Bank, Oakland, CA, ³University of Nevada, Las Vegas, Las Vegas, NV
Background/Purpose: Severe COVID-19 infection resulting in hospitalization shares features with frequently fatal cytokine storm syndromes (CSS), such as hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome…
Abstract Number: 0014 • ACR Convergence 2025
NKX019, an allogeneic off-the-shelf CD19 targeting CAR-NK cell therapy, induces deep CD19+ B cell depletion in hematological malignancy and models of autoimmune disease
Mira Tohmé, Meriam Vejiga, Wendy Yu, Emily Kang, Katharine Yu, Jessica Sood, Ivan Chan, Kyle Hansen, David Shook and Phung Gip, Nkarta, South San Francisco, CA
Background/Purpose: Autologous CAR T-cell therapies have remarkable clinical activity in autoimmune disease (AD) via B-cell targeting, with many patients achieving durable, drug-free remission. However, safety…
Abstract Number: L17 • ACR Convergence 2024
Allogenic CD19 CAR NK Cells Therapy in Refractory Systemic Lupus Erythematosus: An Open-label, Single Arm, Prospective and Interventional Clinical Trial
Yiyi Yu¹, Ruina Kong¹, Xia Xu¹, Suxuan Liu¹, Qian Chen¹, Xiaofang Li², Ming Sun², Jianmin Yang¹, Dongbao Zhao¹ and Jie Gao¹, ¹Changhai Hospital, Shanghai, China, ²Rui Therapeutics, Nanjing, China
Background/Purpose: Treatment of systemic lupus erythematosus (SLE) typically necessitates long-term immunosuppression with hormones, immunosuppressants and biologics. CD19-targeting chimeric antigen receptor (CAR) T cells have shown excellent…
Abstract Number: 1763 • ACR Convergence 2024
Circulating NK and CD8+ Cytotoxic T Cells in Treatment Naïve JDM Demonstrate Higher Cytotoxic and Interferon Signature as Compared to Childhood-Onset SLE
Qinmengge Li¹, Celine Berthier¹, Christine Goudsmit¹, Sophia Matossian¹, Rachael Wasikowski², Johann Gudjonsson¹, J. Michelle Kahlenberg¹, Lam C. Tsoi² and Jessica Turnier³, ¹University of Michigan, Ann Arbor, MI, ²Michigan, Dept. of Dermatology, Ann Arbor, MI, ³University of Michigan, Saline, MI
Background/Purpose: Juvenile dermatomyositis (JDM) and childhood-onset systemic lupus erythematosus (cSLE) are pediatric autoimmune diseases that can present with overlapping clinical features yet have unique tropism…
Abstract Number: 1782 • ACR Convergence 2024
DOCK2 Mutations and Hyper-Inflammatory Syndromes
Randy Cron, Mingce Zhang and Prescott Atkinson, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Cytokine storm syndromes (CSS) are frequently fatal hyper-inflammatory complications of a variety of oncologic, rheumatic, and infectious diseases. Many patients with CSS possess heterozygous…
Abstract Number: 1786 • ACR Convergence 2024
Select Immune Cell Dysregulation Identifies Clinically Quiescent Patients at Risk of Flare Who Stop Mycophenolate Mofetil While Continuing Hydroxychloroquine
Christian Wright¹, Rufei Lu², Catriona Wagner³, Carla Guthridge⁴, Susan Macwana¹, Eliza Chakravarty⁴, Tammy Utset⁵, Diane Kamen⁶, Gabriel Nicolas Contreras Martin⁷, William McCune⁸, Cynthia Aranow⁹, Kenneth Kalunian¹⁰, Elena Massarotti¹¹, Megan Clowse¹², Brad Rovin¹³, S. Sam Lim¹⁴, Vikas Majithia¹⁵, Richard Looney¹⁶, Maria Dall'Era¹⁷, Doruk Erkan¹⁸, Amit Saxena¹⁹, Nancy Olsen²⁰, Kichul Ko²¹, Ellen Goldmuntz²², William Barry²³, Ashley Pinckney²⁴, ALE06 Clinical Study Team⁴, Judith James⁴ and Joel Guthridge⁴, ¹Oklahoma Medical Research Foundation, Oklahoma City, ²University of California San Francisco, San Bruno, CA, ³Oklahoma Medical Research Foundation, Santa Cruz, CA, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵University of Chicago, Chicago, IL, ⁶Medical University of South Carolina, Charleston, SC, ⁷University of Miami, Key Biscayne, FL, ⁸U Michigan, Ann Arbor, MI, ⁹Feinstein Institutes for Medical Research, New York, NY, ¹⁰University of California San Diego, La Jolla, CA, ¹¹Brigham and Women's Hospital, Boston, MA, ¹²Duke University, Chapel Hill, NC, ¹³The Ohio State University, Columbus, OH, ¹⁴Emory University, Atlanta, GA, ¹⁵Mayo Clinic Florida, Jacksonville, FL, ¹⁶University of Rochester, Rochester, NY, ¹⁷UCSF, Corte Madera, CA, ¹⁸Hospital for Special Surgery, New York, NY, ¹⁹NYU School of Medicine, New York, NY, ²⁰Penn State University/Milton S Hershey, Hershey, PA, ²¹The University of Chicago, Chicago, IL, ²²NIAID/ NIH, Washington, DC, ²³Rho, Inc, Durham, NC, ²⁴Rho, St Louis Park, NC
Background/Purpose: Mycophenolate mofetil (MMF) is commonly used to treat major SLE manifestations; however, it is associated with significant toxicities. Thus, MMF withdrawal is desirable in…
Abstract Number: 2422 • ACR Convergence 2024
Development of a Multiplexed-engineered, Off-the-shelf CAR NK Cell with Unique Multi-Pathogenic Cell Targeting Capacity for the Treatment of Autoimmune Diseases in the Absence of Conditioning Chemotherapy
Anil Bagri¹, Alec Witty¹, Amanda Sims¹, Allan Williams¹, Rina Mbofung¹, Daniel Morales-Mantilla¹, Yang Wang¹, Stacey Moreno¹, Allison Aguilar¹, Cara Bickers¹, Yijia Pan¹, Amber Chang¹, Christine Chen¹, Karina Palomares¹, Lauren Fong¹, Nicholas Brookhouser¹, Berhan Mandefro¹, Sajid Mahmood¹, Ramesh Janani¹, Ramzey Abujarour¹, Tom Lee¹, Raedun Clarke¹, Rebecca Elstrom¹, Frank Cichocki², Lilly Wong¹, Betsy Rezner¹, Jode Goodridge¹, Jeffrey Miller² and Bahram Valamehr¹, ¹Fate Therapeutics Inc., San Diego, CA, ²Department of Medicine, University of Minnesota, Minneapolis, MN
Background/Purpose: Unprecedented clinical data have recently shown that patients with certain highly refractory autoimmune diseases (AI Dz) treated with conditioning chemotherapy (CCT) and autologous anti-CD19…
Abstract Number: 0004 • ACR Convergence 2024
Beyond Antibodies and CAR-T: Topologically Engineered, Superdimeric Antibody NK Engagers and T Cell Engagers for B Cell Depletion Demonstrating Cooperative Binding to Target and Effector Cells
Daniel Capon, Larisa Troitskaya, Marina Fomin, Brendon Frank, Ursula Edman, Benjamin Capon, Brian Law, Steven Chapin, Gavin Lewis, Malcolm Gefter, Juha Punnonen and Nelson Chan, Hinge Bio, Inc., Burlingame, CA
Background/Purpose: The dramatic demonstration of CD19 CAR-T efficacy in systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, and systemic sclerosis by Georg Schett and colleagues (F.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].